<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:32:50Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10560193" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10560193</identifier>
        <datestamp>2023-10-09</datestamp>
        <setSpec>springeropen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Invest New Drugs</journal-id>
              <journal-id journal-id-type="iso-abbrev">Invest New Drugs</journal-id>
              <journal-title-group>
                <journal-title>Investigational New Drugs</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0167-6997</issn>
              <issn pub-type="epub">1573-0646</issn>
              <publisher>
                <publisher-name>Springer US</publisher-name>
                <publisher-loc>New York</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10560193</article-id>
              <article-id pub-id-type="pmcid">PMC10560193</article-id>
              <article-id pub-id-type="pmc-uid">10560193</article-id>
              <article-id pub-id-type="pmid">37556023</article-id>
              <article-id pub-id-type="pmid">37556023</article-id>
              <article-id pub-id-type="publisher-id">1383</article-id>
              <article-id pub-id-type="doi">10.1007/s10637-023-01383-2</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kristeleit</surname>
                    <given-names>Rebecca</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Leary</surname>
                    <given-names>Alexandra</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Delord</surname>
                    <given-names>Jean Pierre</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Moreno</surname>
                    <given-names>Victor</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Oaknin</surname>
                    <given-names>Ana</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Castellano</surname>
                    <given-names>Daniel</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shappiro</surname>
                    <given-names>Geoffrey I.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff7">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Fernández</surname>
                    <given-names>Cristian</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kahatt</surname>
                    <given-names>Carmen</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Alfaro</surname>
                    <given-names>Vicente</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Siguero</surname>
                    <given-names>Mariano</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rueda</surname>
                    <given-names>Daniel</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zeaiter</surname>
                    <given-names>Ali</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Awada</surname>
                    <given-names>Ahmad</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff9">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Santaballa</surname>
                    <given-names>Ana</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff10">10</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zaman</surname>
                    <given-names>Khalil</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff11">11</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sehouli</surname>
                    <given-names>Jalid</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff12">12</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Subbiah</surname>
                    <given-names>Vivek</given-names>
                  </name>
                  <address>
                    <email>Vivek.Subbiah@scri.com</email>
                  </address>
                  <xref ref-type="aff" rid="Aff13">13</xref>
                  <xref ref-type="aff" rid="Aff14">14</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.83440.3b</institution-id><institution-id institution-id-type="ISNI">0000000121901201</institution-id><institution>University College London Cancer Institute, NIHR UCLH Clinical Research Facility and Guy’s and St Thomas’ NHS Foundation Trust, </institution></institution-wrap>London, UK </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0321g0743</institution-id><institution-id institution-id-type="GRID">grid.14925.3b</institution-id><institution-id institution-id-type="ISNI">0000 0001 2284 9388</institution-id><institution>Institut Gustave Roussy, </institution></institution-wrap>Villejuif, France </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03pa87f90</institution-id><institution-id institution-id-type="GRID">grid.417829.1</institution-id><institution-id institution-id-type="ISNI">0000 0000 9680 0846</institution-id><institution>Institut Claudius Regaud, </institution></institution-wrap>Toulousse, France </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.419651.e</institution-id><institution-id institution-id-type="ISNI">0000 0000 9538 1950</institution-id><institution>START Madrid-FJD, Hospital Fundación Jiménez Díaz, </institution></institution-wrap>Madrid, Spain </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.411083.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 0675 8654</institution-id><institution>Gynecologic Cancer Programme; Vall d’Hebrón Institute of Oncology (VHIO), </institution><institution>Hospital Universitari Vall D’Hebrón, </institution></institution-wrap>Barcelona, Spain </aff>
                <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00qyh5r35</institution-id><institution-id institution-id-type="GRID">grid.144756.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 1945 5329</institution-id><institution>Hospital Universitario 12 de Octubre, </institution></institution-wrap>Madrid, Spain </aff>
                <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02jzgtq86</institution-id><institution-id institution-id-type="GRID">grid.65499.37</institution-id><institution-id institution-id-type="ISNI">0000 0001 2106 9910</institution-id><institution>Dana-Farber Cancer Institute, </institution></institution-wrap>Boston, MA USA </aff>
                <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02h694m69</institution-id><institution-id institution-id-type="GRID">grid.425446.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 1770 9243</institution-id><institution>PharmaMar, </institution></institution-wrap>Colmenar Viejo, Spain </aff>
                <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.4989.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 2348 0746</institution-id><institution>Institut Jules Bordet, </institution><institution>HUB, Université Libre De Bruxelles, </institution></institution-wrap>Brussels, Belgium </aff>
                <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="GRID">grid.84393.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 0360 9602</institution-id><institution>Hospital La Fe, </institution></institution-wrap>Valencia, Spain </aff>
                <aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.8515.9</institution-id><institution-id institution-id-type="ISNI">0000 0001 0423 4662</institution-id><institution>University Hospital CHUV, </institution></institution-wrap>Lausanne, Switzerland </aff>
                <aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/001w7jn25</institution-id><institution-id institution-id-type="GRID">grid.6363.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2218 4662</institution-id><institution>Charité – Universitätsmedizin Berlin, </institution></institution-wrap>Berlin, Germany </aff>
                <aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04twxam07</institution-id><institution-id institution-id-type="GRID">grid.240145.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 2291 4776</institution-id><institution>The University of Texas MD Anderson Cancer Center, </institution></institution-wrap>Houston, USA </aff>
                <aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="GRID">grid.419513.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0459 5478</institution-id><institution>Present Address: Sarah Cannon Research Institute, </institution></institution-wrap>1100 Dr. Martin L. King Jr. Blvd., Suite 800, Nashville, TN 37203 USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>9</day>
                <month>8</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>9</day>
                <month>8</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <year>2023</year>
              </pub-date>
              <volume>41</volume>
              <issue>5</issue>
              <fpage>677</fpage>
              <lpage>687</lpage>
              <history>
                <date date-type="received">
                  <day>20</day>
                  <month>4</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>11</day>
                  <month>7</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2023</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <p id="Par1">Second-line treatment of endometrial cancer is an unmet medical need. Lurbinectedin showed promising antitumor activity in a phase I study in combination with doxorubicin in advanced endometrial cancer. This phase 2 Basket trial evaluated lurbinectedin 3.2 mg/m<sup>2</sup> 1-h intravenous infusion every 3 weeks in a cohort of 73 patients with pretreated endometrial cancer. The primary endpoint was overall response rate (ORR) according to RECIST v1.1. Secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS), safety and an exploratory translational study. Confirmed complete (CR) and partial response (PR) was reported in two and six patients, respectively (ORR = 11.3%; 95%CI, 5.0–21.0%). Median DoR was 9.2 months (95%CI, 3.4–18.0 months), median PFS was 2.6 months (95%CI, 1.4–4.0 months) and median OS was 9.3 months (95%CI, 6.1–12.8 months). Molecular subtypes showed differences in PFS rate at 6 months (p53abn 23.7% <italic>vs.</italic> “No Specific Molecular Profile” [NSMP] 42.9%) and median OS (p53abn 6.6 months <italic>vs.</italic> NSMP 16.1 months). The most common treatment-related adverse events (mostly grade 1/2) were fatigue (54.8% of patients), nausea (50.7%), vomiting (26.0%) decreased appetite (17.8%). and constipation, (19.2%). The most common grade 3/4 toxicity was neutropenia (43.8%; grade 4, 19.2%; febrile neutropenia, 4.1%). In conclusion, considering the exploratory aim of this trial and the hints of antitumor activity observed together with a predictable and manageable safety profile, further biomarker-based development of lurbinectedin is recommended in this indication in combination with other agents. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">Clinicaltrials.gov</ext-link> identifier: NCT02454972.</p>
                <sec>
                  <title>Supplementary Information</title>
                  <p>The online version contains supplementary material available at 10.1007/s10637-023-01383-2.</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Lurbinectedin</kwd>
                <kwd>Endometrial cancer</kwd>
                <kwd>Phase 2</kwd>
              </kwd-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© Springer Science+Business Media, LLC, part of Springer Nature 2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Introduction</title>
              <p id="Par2">Endometrial cancer is the sixth most common cause of cancer in females with 417,000 cases every year [<xref ref-type="bibr" rid="CR1">1</xref>]. Patients who progress beyond first-line chemotherapy have a poor prognosis and novel therapy options are urgently needed. The Cancer Genome Atlas (TCGA) study of endometrial cancer identified four molecular subtypes [<xref ref-type="bibr" rid="CR2">2</xref>]. Based on this, the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) Algorithm has been developed to assess endometrial cancer samples and classifies them in four molecular subgroups [<xref ref-type="bibr" rid="CR3">3</xref>]. Several therapeutics are being explored using this biomarker analysis. The TCGA endometrial cancer data expanded the knowledge about the role of different immunotherapeutic approaches based on molecular subtypes. Immune checkpoint inhibitors demonstrated distinct antitumor activities as monotherapy or in combination [<xref ref-type="bibr" rid="CR4">4</xref>]. In microsatellite unstable (microsatellite instability-high) endometrial cancer, immune checkpoint inhibitors showed promising activity in recurrent settings. On the other hand, single immune checkpoint inhibitors showed underwhelming efficacy in microsatellite stable endometrial cancer but this improved using a combination approach.</p>
              <p id="Par3">Lurbinectedin (ZEPZELCA<sup>™</sup>) is an oncogenic transcription inhibitor that binds guanine-rich DNA sequences at gene promoters, evicts oncogenic transcription function and inhibits mRNA synthesis through ubiquitination and degradation of RNA polymerase II [<xref ref-type="bibr" rid="CR5">5</xref>–<xref ref-type="bibr" rid="CR7">7</xref>]. In a Basket, multicenter, open-label, phase 2 study (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> identifier: NCT02454972), nine cohorts of patients with different difficult-to-treat tumor types received lurbinectedin to establish the proof of concept of anticancer activity for potential further clinical development. Based on the results in the small cell cancer (SCLC) cohort [<xref ref-type="bibr" rid="CR8">8</xref>], approval of lurbinectedin was obtained first in the US [<xref ref-type="bibr" rid="CR9">9</xref>] and in several other countries later (Canada, Australia, Switzerland, Singapore, South Korea, Ecuador, Mexico, Arab Emirates or Qatar). More recently, results of other cohort of this Basket trial have shown antitumor activity in relapsed Ewing sarcoma [<xref ref-type="bibr" rid="CR10">10</xref>].</p>
              <p id="Par4">This report focuses on the outcomes of the endometrial cancer cohort. In addition, retrospective biomarker analysis based on TCGA and PromiSe molecular subtypes was explored. This cohort was evaluated because promising antitumor activity was previously found in a phase I study for a combination of doxorubicin plus lurbinectedin in patients with advanced endometrial cancer [<xref ref-type="bibr" rid="CR11">11</xref>]. The overall response rate (ORR) of 42.1% was higher than the 14–16% reported for doxorubicin alone [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>], then suggesting a synergistic effect. Furthermore, another trial evaluating lurbinectedin plus paclitaxel showed an ORR of 27% in a small cohort of 11 patients with pretreated endometrial cancer [<xref ref-type="bibr" rid="CR14">14</xref>]. In this study we report the activity and safety analysis of lurbinectedin monotherapy in addition to a translational exploratory analysis of endometrial molecular subtypes showing better PFS and OS in the <italic>TP53</italic> wild-type, low/absent p53 protein immunohistochemical (IHC) and No Specific Molecular Profile (NSMP) molecular subgroups.</p>
            </sec>
            <sec id="Sec2">
              <title>Methods</title>
              <p id="Par5">The study protocol was approved by the Independent Local Ethics Committee of each participating center and was conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines, and local regulations for clinical trials. Signed informed consent was obtained from all patients prior to any study-specific procedure. Additionally, patients were invited to participate in a translational study designed to identify molecular predictors of response or resistance to lurbinectedin, through an independent informed consent. The trial is registered at <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov">https://www.clinicaltrials.gov</ext-link> as NCT02454972.</p>
              <sec id="Sec3">
                <title>Patient selection</title>
                <p id="Par6">Seventy-three patients with endometrial cancer were treated at 19 investigational sites in Belgium (n = 3), France (n = 17), Germany (n = 2), Spain (n = 23), Switzerland (n = 2), the United Kingdom (n = 9), and the USA (n = 17). Eligibility criteria included patients ≥ 18 years old with pathologically proven diagnosis of endometrial carcinoma; pretreated with one prior adjuvant/advanced chemotherapy-containing line (including platinum or not); measurable disease as per the Response Criteria in Solid Tumors (RECIST) v.1.1 [<xref ref-type="bibr" rid="CR15">15</xref>]; Eastern Cooperative Oncology Group performance status ≤ 2; and adequate major organ function. Patients were excluded if they had: previously received lurbinectedin or trabectedin; prior or concurrent malignant disease unless in complete remission for more than five years; known central nervous system involvement; concomitant unstable or serious medical condition, or impending need for radiotherapy.</p>
              </sec>
              <sec id="Sec4">
                <title>Lurbinectedin treatment</title>
                <p id="Par7">All patients were treated with lurbinectedin 3.2 mg/m<sup>2</sup> administered as a 1-h intravenous (i.v.) infusion every three weeks (q3wk). All patients received antiemetic prophylaxis. Primary granulocyte colony-stimulating factors (G-CSFs) prophylaxis was not allowed. Treatment continued until disease progression, unacceptable toxicity, treatment delay &gt; three weeks; more than two dose reductions; or patient refusal.</p>
              </sec>
              <sec id="Sec5">
                <title>Efficacy and safety assessments</title>
                <p id="Par8">The primary objective of this study was to assess the antitumor activity of lurbinectedin in terms of ORR, primary endpoint, assessed by the investigators. Radiological tumor evaluation was performed every six weeks (two cycles) until Cycle 6, and every nine weeks (three cycles) thereafter. Objective response was to be confirmed at least four weeks later. Secondary efficacy endpoints included disease control rate (ORR or stable disease), duration of response (DoR), progression-free survival (PFS), and OS.</p>
                <p id="Par9">Safety was evaluated in all patients who received at least one lurbinectedin infusion, complete or incomplete, by assessment of adverse events (AEs), clinical laboratory test results, physical examinations and vital signs. Laboratory tests were done weekly during Cycles 1 and 2, and on Day 1 of subsequent cycles. AEs were recorded and coded with the Medical Dictionary for Regulatory Activities (MedDRA), v.21.0. AEs and laboratory values were graded according to the National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE), v. 4.0. All patients were followed until recovery from any lurbinectedin-related AE.</p>
              </sec>
              <sec id="Sec6">
                <title>Translational study</title>
                <p id="Par10">Fifty of 73 treated patients (68.5%) had available archived formalin-fixed paraffin-embedded tumor samples and consented to participate in an optional translational study. In order to characterize patients’ tumors, a next generation sequencing (NGS) custom gene panel was performed, targeting 151 genes involved in cancer pathogenesis and DNA-repair (see Supplemental <xref rid="MOESM1" ref-type="media">Methods</xref>). Data of sufficient quality was obtained for 42 patients. Moreover, to classify patients into four endometrial cancer molecular subgroups, two additional techniques were performed: microsatellite instability (MSI) status by fluorescent polymerase chain reaction (PCR) and IHC p53 protein staining (see Supplemental <xref rid="MOESM1" ref-type="media">Methods</xref>). Analytically valid results were obtained for each technique for 47 and 50 samples respectively. Molecular sub-classification was obtained through an hierarchical algorithm [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]: first, patients with pathogenic mutation in <italic>POLE</italic> gene exonuclease domain (POLE+ subgroup); second, MSI positives (dMMR/MSI subgroup); third, high staining abnormal p53 IHC (&gt; 20% stained cells) and/or carriers of deleterious class 5 <italic>TP53</italic> mutations (p53 abnormal subgroup, p53 abn) (see Supplemental <xref rid="MOESM1" ref-type="media">Methods</xref>) and, finally, the remaining were considered as “No Specific Molecular Profile” (NSMP subgroup).</p>
              </sec>
              <sec id="Sec7">
                <title>Statistical methods</title>
                <p id="Par11">Up to 50 evaluable patients were to be recruited to test the null hypothesis that 10% or less patients get a response (p ≤ 0.10) <italic>versus</italic> the alternative hypothesis that 25% or more patients get a response (p ≥ 0.25). The variance of the standardized test was based on the null hypothesis. The type I error (alpha) associated with this one-sided test is 0.025 and the type II error (beta) is 0.144; hence, statistical power is ~86%. With these assumptions, if the number of patients who achieve a confirmed response is ≥ 10, then this would allow the rejection of the null hypothesis.</p>
                <p id="Par12">Initially, 15 patients were to be included in a first stage. If one confirmed response occurred in the first 15 evaluable patients, recruitment had to continue up to 25 evaluable patients. Two of the first 15 patients had confirmed partial response (PR) to lurbinectedin treatment and, therefore, recruitment continued. Due to the signs of activity also observed in combination with doxorubicin [<xref ref-type="bibr" rid="CR11">11</xref>], paclitaxel [<xref ref-type="bibr" rid="CR14">14</xref>] or irinotecan [<xref ref-type="bibr" rid="CR18">18</xref>], a protocol amendment was implemented to include 50 evaluable patients but, finally, because of the fast recruitment until the 50 evaluable patients were evaluated, 73 patients were enrolled and treated.</p>
                <p id="Par13">Descriptive statistics were used. Non-continuous variables are described in frequency tables using counts and percentages. Continuous variables are described by median, minimum and maximum. Binomial exact estimates and its 95% confidence interval (CI) were calculated for the evaluation of the main endpoint (ORR). The Kaplan-Meier method was used to analyze DoR, PFS and OS. For the translational sub-study analysis, the correlation between mutational status and OS or PFS was evaluated by a Cox regression analysis and Kaplan-Meier curves represented. SAS and R software were used to generate statistical outputs.</p>
              </sec>
            </sec>
            <sec id="Sec8">
              <title>Results</title>
              <sec id="Sec9">
                <title>Patient characteristics</title>
                <p id="Par14">Seventy-three patients were recruited and treated with lurbinectedin between 30 October 2016 and 19 April 2017. Cut-off for final analysis of all cohorts in this Basket study was 16 November 2020. Most patients were white (61.6%), with ECOG PS 0–1 (91.8%), and with a median age of 64 years (range, 32–80 years; 49.3% were ≥ 65 years old) (Table <xref rid="Tab1" ref-type="table">1</xref>). The most common histological types were endometrioid (61.6%) and serous (27.4%). The median number of metastatic sites involved at baseline was 2 (range, 1–7), with 45.2% of patients having ≥ 3 disease sites. Lymph nodes (61.6%), lung (46.6%), peritoneum (45.2%) and liver (31.5%) were the most common disease sites. Sixty-two patients (84.9%) had previously undergone surgery. Prior radiotherapy had been administered to 39 patients (53.4%). The patients had received a median of one prior line of chemotherapy for advanced disease (range, 0–4 lines). The most common prior agents were carboplatin (95.9%) and paclitaxel (95.9%). ORR to last prior line was 37.0%.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics of the patients (n = 73)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><bold>n</bold></th><th align="left"><bold>%</bold></th></tr></thead><tbody><tr><td align="left"><bold>Age: median (range), years</bold></td><td align="left" colspan="2">64 (32–80)</td></tr><tr><td align="left" colspan="3"><bold>Race</bold></td></tr><tr><td align="left">  White</td><td align="left">45</td><td char="." align="char">61.6</td></tr><tr><td align="left">  Other <sup>a</sup></td><td align="left">22</td><td char="." align="char">30.1</td></tr><tr><td align="left">  Black of African American</td><td align="left">5</td><td char="." align="char">6.8</td></tr><tr><td align="left">  Asian</td><td align="left">1</td><td char="." align="char">1.4</td></tr><tr><td align="left" colspan="3"><bold>ECOG PS status</bold></td></tr><tr><td align="left">  0–1</td><td align="left">67</td><td char="." align="char">91.8</td></tr><tr><td align="left">  2</td><td align="left">6</td><td char="." align="char">8.2</td></tr><tr><td align="left"><bold>BSA: median (range), m</bold><sup><bold>2</bold></sup></td><td align="left" colspan="2">1.8 (1.3–2.6)</td></tr><tr><td align="left"><bold>Albumin: median (range), g/dL</bold></td><td align="left" colspan="2">4.1 (2.7–4.7)</td></tr><tr><td align="left" colspan="3"><bold>Stage at diagnosis</bold></td></tr><tr><td align="left">  Early</td><td align="left">23</td><td char="." align="char">31.5</td></tr><tr><td align="left">  Locally advanced</td><td align="left">27</td><td char="." align="char">37.0</td></tr><tr><td align="left">  Metastatic</td><td align="left">23</td><td char="." align="char">31.5</td></tr><tr><td align="left" colspan="3"><bold>Histological type</bold></td></tr><tr><td align="left">  Endometrioid</td><td align="left">45</td><td char="." align="char">61.6</td></tr><tr><td align="left">  Serous</td><td align="left">20</td><td char="." align="char">27.4</td></tr><tr><td align="left">  Clear cell</td><td align="left">4</td><td char="." align="char">5.5</td></tr><tr><td align="left">  Carcinosarcoma</td><td align="left">3</td><td char="." align="char">4.1</td></tr><tr><td align="left">  Other <sup>b</sup></td><td align="left">1</td><td char="." align="char">1.4</td></tr><tr><td align="left"><bold>No. of sites at baseline: median (range)</bold></td><td align="left" colspan="2">2 (1–7)</td></tr><tr><td align="left">  ≥ 3 sites</td><td align="left">33</td><td char="." align="char">45.2</td></tr><tr><td align="left" colspan="3"><bold>Most common sites of disease at baseline</bold></td></tr><tr><td align="left">  Lymph nodes</td><td align="left">45</td><td char="." align="char">61.6</td></tr><tr><td align="left">  Lung</td><td align="left">34</td><td char="." align="char">46.6</td></tr><tr><td align="left">  Peritoneum</td><td align="left">33</td><td char="." align="char">45.2</td></tr><tr><td align="left">  Liver</td><td align="left">23</td><td char="." align="char">31.5</td></tr><tr><td align="left">  Primary site</td><td align="left">15</td><td char="." align="char">20.5</td></tr><tr><td align="left">  Soft tissue</td><td align="left">13</td><td char="." align="char">17.8</td></tr><tr><td align="left">  Bone</td><td align="left">9</td><td char="." align="char">12.3</td></tr><tr><td align="left">  Pleura</td><td align="left">6</td><td char="." align="char">8.2</td></tr><tr><td align="left"><bold>Bulky disease (one lesion &gt; 50 mm)</bold></td><td align="left">16</td><td char="." align="char">21.9</td></tr><tr><td align="left" colspan="3"><bold>Prior therapy</bold></td></tr><tr><td align="left">  Surgery</td><td align="left">62</td><td char="." align="char">84.9</td></tr><tr><td align="left">  Radiotherapy</td><td align="left">39</td><td char="." align="char">53.4</td></tr><tr><td align="left"><bold>No. of prior advanced chemotherapy lines: median (range)</bold></td><td align="left" colspan="2">1 (0–4)</td></tr><tr><td align="left" colspan="3"> Most common prior agents</td></tr><tr><td align="left">  Platinum compounds</td><td align="left">72</td><td char="." align="char">98.6</td></tr><tr><td align="left">  Taxanes</td><td align="left">70</td><td char="." align="char">95.9</td></tr><tr><td align="left">  Anthracyclines</td><td align="left">4</td><td char="." align="char">5.5</td></tr><tr><td align="left">  Bevacizumab</td><td align="left">4</td><td char="." align="char">5.5</td></tr><tr><td align="left">  Immunotherapy (Pembrolizumab)</td><td align="left">1</td><td char="." align="char">1.4</td></tr><tr><td align="left">  mTOR inhibitors (Everolimus)</td><td align="left">1</td><td char="." align="char">1.4</td></tr><tr><td align="left">  PARPi (Olaparib)</td><td align="left">1</td><td char="." align="char">1.4</td></tr><tr><td align="left" colspan="3"><bold>Prior endocrine therapy</bold></td></tr><tr><td align="left">  Aromatase inhibitors</td><td align="left">8</td><td char="." align="char">11.9</td></tr><tr><td align="left">  Progestogens</td><td align="left">8</td><td char="." align="char">11.0</td></tr><tr><td align="left">  Gonadotropin-releasing hormone analogues</td><td align="left">1</td><td char="." align="char">1.4</td></tr><tr><td align="left">  Tamoxifen</td><td align="left">1</td><td char="." align="char">1.4</td></tr><tr><td align="left" colspan="3"><bold>Best response to last therapy</bold></td></tr><tr><td align="left">  CR</td><td align="left">7</td><td char="." align="char">9.6</td></tr><tr><td align="left">  PR</td><td align="left">20</td><td char="." align="char">27.4</td></tr><tr><td align="left">  SD</td><td align="left">13</td><td char="." align="char">17.8</td></tr><tr><td align="left">  PD</td><td align="left">15</td><td char="." align="char">20.5</td></tr><tr><td align="left">  Unknown/not available</td><td align="left">18</td><td char="." align="char">24.7</td></tr></tbody></table><table-wrap-foot><p>Data shown are n (%) of patients except for median (range)</p><p><italic>BSA</italic> body surface area, <italic>CR</italic> complete response, <italic>ECOG PS</italic> Eastern Cooperative Oncology Group Performance Status, <italic>PARP</italic> poly (ADP-ribose) polymerase, <italic>PD</italic> disease progression, <italic>PR</italic> partial response, <italic>SD</italic> stable disease</p><p><sup>a</sup>Two patients were Hispanic or Latino. Furthermore, patients recruited in France and Belgium had not race available because of specific ethical requirements in these countries</p><p><sup>b</sup>Endometrial stromal sarcoma (epithelioid)</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec10">
                <title>Lurbinectedin treatment</title>
                <p id="Par15">A total of 378 cycles were administered to the 73 treated patients. The median number of cycles per patient was 4 (range, 1–22 cycles), with 31.5% of patients having received ≥ 6 cycles. The median relative dose intensity was 97.7% (range, 64.9–102.9%). Twenty patients had treatment-related dose delays, being hematological toxicity the most common reason: grade 2–4 neutropenia in 13 patients and grade 3 anemia in two patients. Lurbinectedin dose was reduced due to treatment-related reasons in 6.9% of cycles in 20 patients, being hematological toxicity the most common cause: grade 2-4 neutropenia in eight patients and eight cycles; grade 3/4 febrile neutropenia in two patients and two cycles; and grade 3 leukopenia in one patient and one cycle. Of note, the protocol stated that in case of grade 4 neutropenia, lurbinectedin dose had to be reduced instead of continuing at the same dose with granulocyte colony-stimulating factor (G-CSF) prophylaxis.</p>
              </sec>
              <sec id="Sec11">
                <title>Efficacy results</title>
                <p id="Par16">Seventy-one patients were evaluable for efficacy (Table <xref rid="Tab2" ref-type="table">2</xref>). Two patients were not evaluable due to patient refusal prior to the first disease measurement, and death because of grade 5 septic shock considered unrelated to the study treatment in Cycle 1.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Efficacy results with lurbinectedin treatment in patients with pretreated endometrial cancer (n = 71 evaluable patients)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><bold>RECIST responses (n, %)</bold></th><th align="left"/></tr></thead><tbody><tr><td align="left">  CR</td><td align="left">2 (2.9%)</td></tr><tr><td align="left">  PR</td><td align="left">6 (8.5%)</td></tr><tr><td align="left">  SD</td><td align="left">29 (40.8%)</td></tr><tr><td align="left">    SD ≥ 4 months</td><td align="left">17 (23.9%)</td></tr><tr><td align="left">  PD</td><td align="left">30 (42.3%)</td></tr><tr><td align="left">  Not evaluable</td><td align="left">4 (5.6%)</td></tr><tr><td align="left">  ORR, % (95%CI)</td><td align="left">11.3% (5.0–21.0%)</td></tr><tr><td align="left">  Clinical benefit rate (CR + PR + SD ≥ 4 months), % (95%CI)</td><td align="left">35.2% (24.2–47.5%)</td></tr><tr><td align="left">  Disease control rate <sup>b</sup> (CR + PR + SD), % (95%CI)</td><td align="left">52.1% (39.9–64.1%)</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left"><bold>Duration of Response (DoR)</bold></th><th align="left"/></tr></thead><tbody><tr><td align="left">  Median, months (95%CI)</td><td align="left">9.2 (3.4–18.0)</td></tr><tr><td align="left">  DoR at 6 months, % (95%CI)</td><td align="left">71.4% (38.0–104.9%)</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left"><bold>Progression-free survival (PFS)</bold></th><th align="left"/></tr></thead><tbody><tr><td align="left">  Median, months (95%CI)</td><td align="left">2.6 (1.4–4.0)</td></tr><tr><td align="left">  PFS at 6 months, % (95%CI)</td><td align="left">29.0% (18.2–39.8%)</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left"><bold>Overall survival (OS)</bold></th><th align="left"/></tr></thead><tbody><tr><td align="left">  Median, months (95%CI)</td><td align="left">9.3 (6.1–12.8)</td></tr><tr><td align="left">  OS at 12 months, % (95%CI)</td><td align="left">45.8% (33.8–75.9%)</td></tr></tbody></table><table-wrap-foot><p><italic>CI</italic> confidence interval, <italic>CR</italic> complete response, <italic>DoR</italic> duration of response, <italic>OS</italic> overall survival, <italic>PD</italic> disease progression, <italic>PFS</italic> progression-free survival, <italic>PR</italic> partial response, <italic>RECIST</italic> Response Evaluation Criteria in Solid Tumors, <italic>SD</italic> stable disease</p></table-wrap-foot></table-wrap></p>
                <p id="Par17">Confirmed complete response (CR) was reported in two patients (2.9%) and partial response (PR) in six patients (8.5%). Stable disease (SD) was observed in 29 patients (40.8%), with 17 of them (23.9%) reaching SD ≥ 4 months. Therefore, ORR was 11.3% (95%CI, 5.0–21.0%). Overall, 47.6% of patients had reduction in target lesions during the treatment period (Fig. <xref rid="Fig1" ref-type="fig">1</xref>A). Objective responses were observed in the two most common histological subtypes: endometrioid (five responses) and serous (two responses). The other response was reported in a patient with endometrial stromal sarcoma (epithelioid). The median of prior lines in responder patients was one (range, 1–4) (Supplemental Table <xref rid="MOESM1" ref-type="media">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p><bold>A</bold> Waterfall plot showing maximum variation of target lesions size with lurbinectedin in patients with pretreated endometrial cancer. <bold>B</bold> Time to progression with last prior therapy (months) <italic>versus</italic> progression-free survival (months) with lurbinectedin in patients with endometrial cancer and clinical benefit (complete response, partial response or stable disease ≥ 4 months). Abbreviations: CR, complete response; NA, not available; PD, disease progression; PR, partial response; SD, stable disease; UK, unknown</p></caption><graphic xlink:href="10637_2023_1383_Fig1_HTML" id="MO1"/></fig></p>
                <p id="Par18">Median DoR was 9.2 months (95%CI, 3.4–18.0 months). Clinical benefit rate (CR + PR + SD ≥ 4 months) and disease control rate (CR + PR + SD) were 35.2% (95%CI, 24.2–47.5%) and 52.1% (95%CI, 39.9–64.1%), respectively (Table <xref rid="Tab2" ref-type="table">2</xref>). Median duration for clinical benefit rate and disease control rate was 7.1 months and 5.6 months, respectively. Time to progression with last prior therapy <italic>versus</italic> PFS with lurbinectedin is shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>B.</p>
                <p id="Par19">Median PFS was 2.6 months (95%CI, 1.4–4.0 months) and PFS rate at 6 months was 29.0% (95%CI, 18.2–39.8%). With a median follow-up of 28.9 months and a censoring rate of 19.8%, median OS was 9.3 months (95%CI, 6.1–12.8 months) (Table <xref rid="Tab2" ref-type="table">2</xref>).</p>
                <p id="Par20">Thirty-five patients (47.9%) received further antitumor medical therapy, nine patients (12.3%) received further radiotherapy and two patients (2.7%) underwent further surgery after lurbinectedin. The most common agents subsequently received were paclitaxel (n = 14; 19.2%) and carboplatin (n = 13; 17.8%).</p>
              </sec>
              <sec id="Sec12">
                <title>Translational study results</title>
                <p id="Par21">In the context of a retrospective translational study, an NGS panel was performed to identify molecular tumor biomarkers that might influence the clinical response to lurbinectedin. The mutational landscape observed was typical for an endometrial cancer cohort [<xref ref-type="bibr" rid="CR2">2</xref>]: <italic>TP53</italic> mutated (54.8% of tumors), <italic>PIK3CA</italic> (38.0%), <italic>PTEN</italic> (21.4%), <italic>KRAS</italic> (26.2%), and <italic>KMT2D</italic> and <italic>ARID1A</italic> (19.0% each) (Fig. <xref rid="Fig2" ref-type="fig">2</xref>A). The most remarkable results are shorter median PFS in patients with <italic>PIK3CA</italic> mutation positive tumors: 2.0 <italic>vs.</italic> 4.0 months in the wild-type group (p = 0.0059), and shorter median OS in patients with <italic>TP53</italic> pathogenic mutation: 6.6 <italic>vs.</italic> 16.1 months in the wild-type group (p = 0.0020) (Supplemental Table <xref rid="MOESM1" ref-type="media">2</xref> and Supplemental Fig. <xref rid="MOESM1" ref-type="media">1</xref>A-D).<fig id="Fig2"><label>Fig. 2</label><caption><p><bold>A</bold> Oncoplot showing mutational profile on every patient sample, together with histology, tumor grade, p53 immunohistochemistry and molecular subtype classification. <bold>B</bold> Molecular classification algorithm for endometrial cancer patients included in this cohort. Abbreviations: IHC, immunohistochemistry; VOUS, variants of unknown significance; MSI/dMMR, “microsatellite instable/mismatch repair deficient” molecular subgroup; NSMP, “No Specific Molecular Profile” molecular subgroup; p53abn, “p53 abnormal” molecular subgroup including abnormal p53 IHC and nonsense/non-funtional <italic>TP53</italic> mutants</p></caption><graphic xlink:href="10637_2023_1383_Fig2_HTML" id="MO2"/></fig></p>
                <p id="Par22">In addition to the traditional classification, based on staging and histology, last guidelines recommend to incorporate tumor biomarkers to allow endometrial cancer subgroup classification in four molecular subtypes: p53 abnormal, dMMR/MSI+, POLE-mutated, and “no specific molecular profile” (NSMP) [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. To classify patient’s tumors, NGS characterization was complemented with evaluation of MSI status and p53 protein IHC staining (see Supplemental <xref rid="MOESM1" ref-type="media">Methods</xref>). None of the samples was carrier of any described or likely pathogenic <italic>POLE</italic> variant; three samples (7.1%) were MSI positive, 23 samples (54.8%) showed p53/<italic>TP53</italic> inactivation and 16 samples (38.1%) were classified as NSMP (Fig. <xref rid="Fig2" ref-type="fig">2</xref>B). Consistently with observations on <italic>TP53</italic> pathogenic mutation, as under normal conditions wild-type p53 protein is rapidly degraded and inactive p53 accumulates [<xref ref-type="bibr" rid="CR19">19</xref>], patients with high p53 IHC staining showed a numerically shorter mean PFS than p53 low/absent normal tumors (1.7 months <italic>vs.</italic> 2.7 months, p = 0.3309) and a shorter median OS (8.2 months <italic>vs.</italic> 12.8 months, p = 0.0345) (Supplemental Table <xref rid="MOESM1" ref-type="media">3</xref> and Supplemental Fig. <xref rid="MOESM1" ref-type="media">1</xref>E-F).</p>
                <p id="Par23">Molecular subtypes showed differences in PFS, with a difference at 6 months of 19.2% between p53abn and NSMP molecular subgroups, 23.7% (95%CI, 5.8%-41.7%) and 42.9% (95%CI, 18.2%-67.5%) respectively (Supplemental Table <xref rid="MOESM1" ref-type="media">4</xref>). Overall survival was significantly shorter in p53 abnormal group with a median of 6.6 months (95%CI, 3.1–12.1) compared to the NSMP group, with a median of 16.1 months (95%CI, 5.3–26.6) (Supplemental Table <xref rid="MOESM1" ref-type="media">4</xref> and Supplemental Fig. <xref rid="MOESM1" ref-type="media">1</xref>G-H). No significant differences were seen on MSI molecular subgroup (data not shown).</p>
              </sec>
              <sec id="Sec13">
                <title>Safety results</title>
                <p id="Par24">All 73 treated patients were evaluable for safety (Table <xref rid="Tab3" ref-type="table">3</xref>). The most common treatment-related adverse events were fatigue (54.8% of patients), gastrointestinal disorders (nausea, 50.7%, vomiting, 26.0%, and constipation, 19.2%), and metabolism and nutrition disorders (mainly decreased appetite, 17.8%). These adverse events were mostly grade 1/2. The most common treatment-related grade 3/4 AEs and laboratory abnormalities regardless of relationship were hematological disorders including anemia (27.4%), leukopenia (32.9%) and neutropenia (43.8%; grade 4, 19.2%; febrile neutropenia, 4.1%); fatigue (4.1%), nausea (2.7%), diarrhea (2.7%), and increased liver function tests, including increased transaminases (ALT, 4.2%; AST, 1.4%), alkaline phosphatase (5.6%) and GGT (19.2%). Eleven patients (15.1%) received G-CSFs secondary prophylaxis or therapeutic for neutropenia.<table-wrap id="Tab3"><caption><p>Most common laboratory abnormalities and treatment-related adverse events (≥ 10% of patients or grade ≥ 3) in patients with pretreated endometrial cancer (n = 73)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3"/><th align="left" colspan="10"><bold>NCI-CTCAE grade</bold></th></tr><tr><th align="left" colspan="2"><bold>Grade 1–2</bold></th><th align="left" colspan="2"><bold>Grade 3</bold></th><th align="left" colspan="2"><bold>Grade 4</bold></th><th align="left" colspan="2"><bold>Grade 5</bold></th><th align="left" colspan="2"><bold>Total</bold></th></tr><tr><th align="left"><bold>n</bold></th><th align="left"><bold>%</bold></th><th align="left"><bold>n</bold></th><th align="left"><bold>%</bold></th><th align="left"><bold>n</bold></th><th align="left"><bold>%</bold></th><th align="left"><bold>n</bold></th><th align="left"><bold>%</bold></th><th align="left"><bold>n</bold></th><th align="left"><bold>%</bold></th></tr></thead><tbody><tr><td align="left" colspan="11"><bold>Hematological abnormalities (regardless of relationship)</bold></td></tr><tr><td align="left">  Anemia</td><td align="left">46</td><td char="." align="char">63.0</td><td align="left">19</td><td char="." align="char">26.0</td><td align="left">1</td><td char="." align="char">1.4</td><td align="left">-</td><td align="left">-</td><td align="left">66</td><td char="." align="char">90.4</td></tr><tr><td align="left">  Leukopenia</td><td align="left">34</td><td char="." align="char">46.6</td><td align="left">15</td><td char="." align="char">20.5</td><td align="left">9</td><td char="." align="char">12.3</td><td align="left">-</td><td align="left">-</td><td align="left">58</td><td char="." align="char">79.5</td></tr><tr><td align="left">  Neutropenia</td><td align="left">19</td><td char="." align="char">26.0</td><td align="left">18</td><td char="." align="char">24.7</td><td align="left">14</td><td char="." align="char">19.2</td><td align="left">-</td><td align="left">-</td><td align="left">51</td><td char="." align="char">69.9</td></tr><tr><td align="left">  Thrombocytopenia</td><td align="left">30</td><td char="." align="char">41.1</td><td align="left">3</td><td char="." align="char">4.1</td><td align="left">2</td><td char="." align="char">2.7</td><td align="left">-</td><td align="left">-</td><td align="left">35</td><td char="." align="char">47.9</td></tr></tbody></table><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="11"><bold>Biochemical abnormalities (regardless of relationship)</bold><sup><bold>a</bold></sup></td></tr><tr><td align="left">  Creatinine increased <sup>b</sup></td><td align="left">63</td><td char="." align="char">86.3</td><td align="left">2</td><td char="." align="char">2.7</td><td align="left">-</td><td char="." align="char">-</td><td align="left">-</td><td align="left">-</td><td align="left">65</td><td char="." align="char">89.0</td></tr><tr><td align="left">  GGT increased</td><td align="left">37</td><td char="." align="char">50.7</td><td align="left">14</td><td char="." align="char">19.2</td><td align="left">1</td><td char="." align="char">1.4</td><td align="left">-</td><td align="left">-</td><td align="left">52</td><td char="." align="char">71.2</td></tr><tr><td align="left">  ALT increased</td><td align="left">43</td><td char="." align="char">58.9</td><td align="left">3</td><td char="." align="char">4.2</td><td align="left">-</td><td char="." align="char">-</td><td align="left">-</td><td align="left">-</td><td align="left">46</td><td char="." align="char">63.9</td></tr><tr><td align="left">  AST increased</td><td align="left">38</td><td char="." align="char">52.1</td><td align="left">1</td><td char="." align="char">1.4</td><td align="left">-</td><td char="." align="char">-</td><td align="left">-</td><td align="left">-</td><td align="left">39</td><td char="." align="char">54.2</td></tr><tr><td align="left">  AP increased</td><td align="left">32</td><td char="." align="char">43.8</td><td align="left">4</td><td char="." align="char">5.6</td><td align="left">-</td><td char="." align="char">-</td><td align="left">-</td><td align="left">-</td><td align="left">36</td><td char="." align="char">50.0</td></tr><tr><td align="left">  Total bilirubin increased</td><td align="left">9</td><td char="." align="char">12.7</td><td align="left">2</td><td char="." align="char">2.8</td><td align="left">-</td><td char="." align="char">-</td><td align="left">-</td><td align="left">-</td><td align="left">11</td><td char="." align="char">15.5</td></tr><tr><td align="left">  CPK increased</td><td align="left">9</td><td char="." align="char">12.7</td><td align="left">-</td><td char="." align="char">-</td><td align="left">-</td><td char="." align="char">-</td><td align="left">-</td><td align="left">-</td><td align="left">9</td><td char="." align="char">12.7</td></tr></tbody></table><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="11"><bold>Treatment-related adverse events</bold></td></tr><tr><td align="left">  Fatigue</td><td align="left">37</td><td char="." align="char">50.7</td><td align="left">3</td><td char="." align="char">4.1</td><td align="left">-</td><td char="." align="char">-</td><td align="left">-</td><td align="left">-</td><td align="left">40</td><td char="." align="char">54.8</td></tr><tr><td align="left">  Nausea</td><td align="left">35</td><td char="." align="char">47.9</td><td align="left">2</td><td char="." align="char">2.7</td><td align="left">-</td><td char="." align="char">-</td><td align="left">-</td><td align="left">-</td><td align="left">37</td><td char="." align="char">50.7</td></tr><tr><td align="left">  Vomiting</td><td align="left">18</td><td char="." align="char">23.8</td><td align="left">1</td><td char="." align="char">1.4</td><td align="left">-</td><td char="." align="char">-</td><td align="left">-</td><td align="left">-</td><td align="left">19</td><td char="." align="char">26.0</td></tr><tr><td align="left">  Constipation</td><td align="left">14</td><td char="." align="char">19.2</td><td align="left">-</td><td char="." align="char">-</td><td align="left">-</td><td char="." align="char">-</td><td align="left">-</td><td align="left">-</td><td align="left">14</td><td char="." align="char">19.2</td></tr><tr><td align="left">  Decreased appetite</td><td align="left">13</td><td char="." align="char">17.8</td><td align="left">-</td><td char="." align="char">-</td><td align="left">-</td><td char="." align="char">-</td><td align="left">-</td><td align="left">-</td><td align="left">13</td><td char="." align="char">17.8</td></tr><tr><td align="left">  Diarrhea</td><td align="left">9</td><td char="." align="char">12.3</td><td align="left">2</td><td char="." align="char">2.7</td><td align="left">-</td><td char="." align="char">-</td><td align="left">-</td><td align="left">-</td><td align="left">11</td><td char="." align="char">15.1</td></tr><tr><td align="left">  Peripheral neuropathy</td><td align="left">4</td><td char="." align="char">5.5</td><td align="left">1</td><td char="." align="char">1.4</td><td align="left">-</td><td char="." align="char">-</td><td align="left">-</td><td align="left">-</td><td align="left">5</td><td char="." align="char">6.8</td></tr><tr><td align="left">  Abdominal pain</td><td align="left">3</td><td char="." align="char">4.1</td><td align="left">1</td><td char="." align="char">1.4</td><td align="left"/><td char="." align="char"/><td align="left">-</td><td align="left">-</td><td align="left">4</td><td char="." align="char">5.5</td></tr><tr><td align="left">  Febrile neutropenia</td><td align="left">-</td><td char="." align="char">-</td><td align="left">2</td><td char="." align="char">2.7</td><td align="left">1</td><td char="." align="char">1.4</td><td align="left">-</td><td align="left">-</td><td align="left">3</td><td char="." align="char">4.1</td></tr><tr><td align="left">  Peripheral edema</td><td align="left">2</td><td char="." align="char">2.7</td><td align="left">1</td><td char="." align="char">1.4</td><td align="left">-</td><td char="." align="char">-</td><td align="left">-</td><td align="left">-</td><td align="left">3</td><td char="." align="char">4.1</td></tr><tr><td align="left">  Dehydration</td><td align="left">1</td><td char="." align="char">1.4</td><td align="left">1</td><td char="." align="char">1.4</td><td align="left">-</td><td char="." align="char">-</td><td align="left">-</td><td align="left">-</td><td align="left">2</td><td char="." align="char">2.8</td></tr><tr><td align="left">  Sepsis</td><td align="left">-</td><td char="." align="char">-</td><td align="left">-</td><td char="." align="char">-</td><td align="left">-</td><td char="." align="char">-</td><td align="left">1</td><td align="left">1.4 <sup>c</sup></td><td align="left">1</td><td char="." align="char">1.4</td></tr><tr><td align="left">  Ataxia</td><td align="left">-</td><td char="." align="char">-</td><td align="left">1</td><td char="." align="char">1.4</td><td align="left">-</td><td char="." align="char">-</td><td align="left">-</td><td align="left">-</td><td align="left">1</td><td char="." align="char">1.4</td></tr><tr><td align="left">  Vertigo</td><td align="left">-</td><td char="." align="char">-</td><td align="left">1</td><td char="." align="char">1.4</td><td align="left">-</td><td char="." align="char">-</td><td align="left">-</td><td align="left">-</td><td align="left">1</td><td char="." align="char">1.4</td></tr></tbody></table><table-wrap-foot><p><italic>AP</italic> alkaline phosphatase, <italic>ALT</italic> alanine aminotransferase, <italic>AST</italic> aspartate aminotransferase, <italic>CPK</italic> creatine phosphokinase, <italic>GGT</italic> gamma glutamyltransferase, <italic>NCI-CTCAE</italic> National Cancer Institute Common Terminology Criteria for Adverse Events v.4</p><p><sup>a</sup>Based on patients with laboratory data available (ranging from 71 to 73 depending on the parameter)</p><p><sup>b</sup>Version 4.0 of NCI-CTCAE grades creatinine increases from baseline, even if creatinine values remain normal</p><p><sup>c</sup>One patient died due to grade 5 sepsis infection after two cycles</p></table-wrap-foot></table-wrap></p>
                <p id="Par25">One patient died due to treatment-related grade 5 sepsis infection after two cycles (Table <xref rid="Tab3" ref-type="table">3</xref>). This case was associated with severe neutropenia. During hospitalization, blood culture was positive for <italic>Klebsiella</italic>, <italic>Escherichia coli</italic>, <italic>Streptococcus viridans</italic> and <italic>Streptococcus</italic> and CT-scan showed disease progression that was later confirmed in the autopsy.</p>
                <p id="Par26">Most patients (n = 59; 80.8%) discontinued the study treatment due to disease progression. With respect to the other 14 patients, five (6.8%) died while on treatment (three due to disease progression, one due to grade 5 septic shock unrelated to treatment, and one due to treatment-related grade 5 sepsis, above explained); five (6.8%) refused to continue treatment; one (1.4%) discontinued lurbinectedin therapy due to a treatment-related adverse event: persistence of peripheral neuropathy (grade 2 was present at baseline and worsened to grade 3); and the other three patients discontinued lurbinectedin due to adverse events unrelated to the study treatment (n = 1) or because of investigator decision based on benefit-risk balance (n = 2).</p>
              </sec>
            </sec>
            <sec id="Sec14">
              <title>Discussion</title>
              <p id="Par27">This cohort from a phase 2 exploratory Basket study included 73 patients with pretreated endometrial cancer who received therapy with single-agent lurbinectedin. ORR according to RECIST v.1.1 was 11.3% (95%CI, 5.0–21.0%). Responses were mostly observed in patients with endometrioid tumors and the median of prior lines was one. These results (eight objective responses) were lower than the threshold of ≥ 10 confirmed responses established in the statistical hypothesis for this endometrial carcinoma cohort. However, although the cohort did not meet the planned hypothesis, hints of antitumor activity were observed, with two patients achieving complete response and six patients with partial responses in a quite heterogeneous cohort that included patients with different number of prior lines administered (up to four previous lines), different histology subtypes (e.g., carcinosarcoma, endometrial stromal sarcoma), and not characterized molecularly at study entry according to current guidelines [<xref ref-type="bibr" rid="CR20">20</xref>]. Of note, median duration of response was prolonged (9.2 months). This duration of response was similar to that found for physician’s choice following platinum-based therapy in patients with advanced endometrial cancer in a recent phase 3 study [<xref ref-type="bibr" rid="CR21">21</xref>].</p>
              <p id="Par28">Studies in small cohorts of patients of lurbinectedin in combination with other drugs have shown to increase the single-agent activity in pretreated endometrial cancer. For instance, in combination with doxorubicin (ORR = 42% and median DoR = 7.5 months) [<xref ref-type="bibr" rid="CR11">11</xref>], paclitaxel (ORR = 27% and median DoR = 6.1 months) [<xref ref-type="bibr" rid="CR14">14</xref>], or irinotecan (ORR = 30%; median DoR not available) [<xref ref-type="bibr" rid="CR18">18</xref>].</p>
              <p id="Par29">Retrospective tumor molecular and genomic profiling have shown different lurbinectedin response depending on the presence of mutations on particular genes, protein levels and specific molecular subtypes, with better PFS and OS in the <italic>TP53</italic> wild-type, low/absent p53 protein IHC and NSMP molecular subgroup. These biomarkers/molecular classification might help to identify those patients who could get more benefit from lurbinectedin alone or in combination. However, as molecular subgroups are known to have a prognostic value [<xref ref-type="bibr" rid="CR17">17</xref>] and no control arm was included in this trial, these results should be taken with caution and considered merely as hypothesis-generating. In any case, our results exemplified how molecular testing/classification should be incorporated in endometrial cancer clinical trials in the same extension as it is nowadays recommended to be included in the clinical management of endometrial cancer [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p>
              <p id="Par30">Lurbinectedin administered at 3.2 mg/m<sup>2</sup> as a 1-h i.v. q3wk infusion in patients with pretreated endometrial carcinoma demonstrates a predictable and manageable safety profile, with the main toxicity being reversible myelosuppression, fatigue and nausea/vomiting. Overall, the safety profile reported for lurbinectedin in this cohort of patients agrees with the results observed previously in patients with other solid tumors such as breast cancer [<xref ref-type="bibr" rid="CR22">22</xref>], Ewing sarcoma [<xref ref-type="bibr" rid="CR10">10</xref>] neuroendocrine tumors [<xref ref-type="bibr" rid="CR23">23</xref>], ovarian cancer [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>], or SCLC [<xref ref-type="bibr" rid="CR8">8</xref>].</p>
              <p id="Par31">In conclusion, the current efficacy results suggest that antitumor activity of lurbinectedin could be improved in patients with pretreated endometrial cancer when administered in combination with other agents and in populations with previous molecular classification. Immunotherapy added to chemotherapy has shown promising results in the first-line treatment of endometrial cancer [<xref ref-type="bibr" rid="CR26">26</xref>–<xref ref-type="bibr" rid="CR30">30</xref>]. Immunotherapy currently is placed in the second-line setting in advanced treatment of endometrial cancer, as single agent in deficient mismatch repair (dMMR), or in combination (e.g., pembrolizumab-lenvatinib) in proficient mismatch repair (pMMR). The evaluation of lurbinectedin combined with an immune checkpoint inhibitor in pMMR is warranted.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <sec id="Sec15">
                <title>Supplementary Information</title>
                <p>Below is the link to the electronic supplementary material.
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="10637_2023_1383_MOESM1_ESM.docx"><caption><p>Supplementary file1 (DOCX 230 KB)</p></caption></media></supplementary-material></p>
              </sec>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn>
                <p>
                  <bold>Publisher's Note</bold>
                </p>
                <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgements</title>
              <p>We gratefully acknowledge the patients, their families and the investigator teams. Vivek Subbiah is an Andrew Sabin Family Foundation Fellow at The University of Texas MD Anderson Cancer Center. Vivek Subbiah acknowledges support of The Jacquelyn A. Brady Fund.</p>
            </ack>
            <notes notes-type="author-contribution">
              <title>Author contributions</title>
              <p>Rebecca Kristeleit: Investigation, Resources, Writing – review &amp; editing. Alexandra Leary: Investigation, Resources, Writing – review &amp; editing. Jean Pierre Delord: Investigation, Resources, Writing – review &amp; editing. Victor Moreno: Investigation, Resources, Writing – review &amp; editing. Ana Oaknin: Investigation, Resources, Writing – review &amp; editing. Daniel Castellano: Investigation, Resources, Writing – review &amp; editing. Geoffrey I. Shapiro: Investigation, Resources, Writing – review &amp; editing. Cristian Fernández: Conceptualization, Methodology, Writing – Original Draft, Writing – review &amp; editing, Supervision. Carmen Kahatt: Conceptualization, Methodology, Writing – review &amp; editing, Supervision. Vicente Alfaro: Methodology, Writing – Original Draft, Writing – review &amp; editing. Mariano Siguero: Methodology, Formal analysis, Writing – review &amp; editing. Ali Zeaiter: Methodology, Writing – review &amp; editing, Supervision. Ahmad Awada: Investigation, Resources, Writing – review &amp; editing. Anna Santaballa: Investigation, Resources, Writing – review &amp; editing. Khalil Zaman: Investigation, Resources, Writing – review &amp; editing. Jalid Sehouli: Investigation, Resources, Writing – review &amp; editing. Vivek Subbiah: Conceptualization, Investigation, Resources, Writing – Original Draft, Writing – review &amp; editing.</p>
            </notes>
            <notes notes-type="funding-information">
              <title>Funding</title>
              <p>The study was funded by Pharma Mar S.A, including partial funding by grants from the Centro para el Desarrollo Tecnológico Industrial (CDTI) during the conduct of the study (grant number IDI-20150006). VS is supported by a US National Institutes of Health (NIH) grant (no. R01CA242845 and R01CA273168); MD Anderson Cancer Center Department of Investigational Cancer Therapeutics is supported by the Cancer Prevention and Research Institute of Texas (no. RP1100584), the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (no. 1U01 CA180964), NCATS (Center for Clinical and Translational Sciences) Grant (no. UL1 TR000371), and the MD Anderson Cancer Center Support Grant (no. P30 CA016672).</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Data availability</title>
              <p>Individual participant data are not publicly available since this requirement was not anticipated in the study protocol considering that this trial started patient enrolment in 2015. Clinical trial summary results were placed in the European Clinical Trials Database (EudraCT; <ext-link ext-link-type="uri" xlink:href="https://eudract.ema.europa.eu">https://eudract.ema.europa.eu</ext-link>; study 2014-003773-42) and <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> (Identifier: NCT02454972).</p>
            </notes>
            <notes>
              <title>Declarations</title>
              <notes id="FPar1">
                <title>Ethical approval</title>
                <p id="Par32">All procedures performed were in accordance with the ethical standards of the institutional and/or national research committees, and with the Declaration of Helsinki or comparable ethical standards.</p>
              </notes>
              <notes id="FPar2">
                <title>Informed consent</title>
                <p id="Par33">Written informed consent was obtained from all patients included in the study.</p>
              </notes>
              <notes id="FPar3" notes-type="COI-statement">
                <title>Competing interests</title>
                <p id="Par34">Alexandra Leary has grants or contracts from Agenus, Astra Zeneca, BMS, GSK, Iovance, MSD, OSE Immuno, Roche as principal investigator in clinical trials and from ARCAGY-GYENCO, AZ, Sanofi for translational research; has payment as invited speaker from Astra Zeneca, Clovis, GSK, Kephren publishing, Medscape; payment for consultancy from GLG and Orion, and payment for writing engagement from Onko+; has participation in Advisory Boards from Ability Pharma, Apmonia, Astra Zeneca, Blueprint, Clovis, GSK, Merck Serono, MSD, Tesaro and Zentaris; has participation in a steering committee from MSD; was IDMC member or chair for Clovis and Pfizer; and participated in an Academic Research Project for LX Repair and Owkin. Ana Oaknin has grants or contracts from Abbvie Deutschland Gmbh &amp; Co Hg, Ability Pharmaceuticals, Advaxis, Agenus, Aprea Therapeutics AB, Astrazeneca AB, Beigene USA, Inc., Belgian Gynaecological Oncology Group (BGOG), Bristol‐Myers Squibb International Corporation (BMSM Clovis Oncology, Corcept Therapeutics, Eisai, F. Hoffmann‐La Roche, Grupo Español de Investigación en Cáncer de Ovario (GEICO), Immunogen, Iovance Biotherapeutics, Lilly, Medimmune, Merck Healthcare, Merck Sharp &amp; dohme, Millennium Pharmaceuticals, Mundipharma Research, Novartis Farmacéutica, Regeneron Pharmaceuticals, Seagen, Seattle Genetics, Sutro Biopharma, Tesaro, University Health Network, and Werastem; has payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from ESMO, Edizioni Minerva Medica SpA and Doctaforum Servicios S.L.; has support for attending meetings and/or travel from AstraZeneca; Clovis Oncology; PharmaMar, and Roche; and participation on a Data Safety Monitoring Board or Advisory Board from Agenus, AstraZeneca, Clovis Oncology, Inc., Corcept Therapeutics, Deciphera Pharmaceutical, Eisai Europe Limited, EMD Serono, Inc., F. Hoffmann‐La Roche, GlaxoSmithKline, Immunogen, KL Logistics, Medison Pharma, Merck Sharp &amp; Dohme de España, Mersana Therapeutics, Novocure GmbH, Pharma Mar, prIME Oncology, ROCHE FARMA, Sattucklabs, and Sutro Biopharma, Inc., as well as participation to non‐remunerated activities and non‐remunerated leadership roles for GCIC and GEICO. Daniel Castellano have payment for Advisory Board or Expert Opinion from Pfizer, Roche, BMS, MSD, Astellas, Astra Zeneca, Novartis, Gilead, Ipsen, Pierre Fabre, Sanofi, Eisai, Janssen and GSK. Geoffrey. I. Shappiro has payment to Dana-Farber Cancer Institute from PharmaMar for conduct of the clinical trial; has sponsored research agreement with payment to DFCI from Merck KGaA/EMD-Serono, Merck &amp; Co. and Lilly; has funding for investigator-initiated clinical trials to DFCI from Pfizer; consulting fees from XinThera, Inc.; has patent issued to Cyclacel Pharmaceuticals and Geoffrey I. Shapiro for dosage regimen for sapacitabine and seliciclib, and pending to Liam Cornell and Geoffrey I. Shapiro for compositions and methods for predicting response and resistance to CDK4/6 inhibition; and has participation on advisory boards for Pfizer, Eli Lilly, Merck KGaA/EMD-Serono, Bicycle Therapeutics, Fusion Pharmaceuticals, Cybrexa Therapeutics, Bayer, Boehringer Ingelheim, ImmunoMet, Asana, Artios, Atrin, Concarlo Holdings, Syros, Zentalks, CytomX Therapeutics, Blueprint Medicines, Kymera Therapeutics, and Janssen. Cristian Fernández, Carmen Kahatt, Vicente Alfaro, Mariano Siguero, Daniel Rueda and Ali Zeaiter have personal fees for salary as full time employee from PharmaMar S.A. Cristian Fernández, Carmen Kahatt, Vicente Alfaro, Daniel Rueda and Ali Zeaiter are stock ownership of PharmaMar S.A. Ahmad Awada has advisory role with Amgen, AstraZeneca, Bayer, Daiichi, EISAI, Genomic Health, Hengrui, Innate, Ipsen, Leo Pharma, Lilly, Merck, MSD, Novartis, Pfizer and Seattle Genetics; has speaker fees with Amgen, AstraZeneca, Bayer, Daiichi, EISAI, Genomic Health, Ipsen, Leo Pharma, Lilly, Merck, MSD, Novartis, Pfizer and Seattle Genetics; and has research grants to his Institute by BSM and Roche. Vivek Subbiah received grants from PharmaMar, Eli Lilly/LOXO Oncology, Blueprint Medicines Corporation, Turning PointTherapeutics and Boston Pharmaceuticals; and grants fromHelsinn Pharmaceuticals during the conduct of the study; in addition, Vivek Subbiah received a grant and advisory board/consultant position with Eli Lilly/Loxo Oncology during the conduct of the study; research grants from Roche/Genentech, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, D3, Pfizer, Multivir, Amgen, AbbVie, Alfa-sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint Medicines, Altum, Dragonfly Therapeutics, Takeda, National Comprehensive Cancer Network, NCI-CTEP, University of Texas MD Anderson Cancer Center, Turning Point Therapeutics, Boston Pharmaceuticals, Novartis, PharmaMar and Medimmune; an advisory board/consultant position with Helsinn, Incyte, QED Pharma, Daiichi-Sankyo, Signant Health, Novartis, Relay therapeutics, Roche and Medimmune; travel funds from PharmaMar, Incyte, ASCO, ESMO; and other support from Medscape, all outside the submitted work. The remaining authors made no disclosures.</p>
              </notes>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sung</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Ferlay</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Siegel</surname>
                      <given-names>RL</given-names>
                    </name>
                    <name>
                      <surname>Laversanne</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Soerjomataram</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Jemal</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Bray</surname>
                      <given-names>F</given-names>
                    </name>
                  </person-group>
                  <article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>
                  <source>CA Cancer J Clin</source>
                  <year>2021</year>
                  <volume>71</volume>
                  <fpage>209</fpage>
                  <lpage>249</lpage>
                  <pub-id pub-id-type="doi">10.3322/caac.21660</pub-id>
                  <?supplied-pmid 33538338?>
                  <pub-id pub-id-type="pmid">33538338</pub-id>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <collab>Cancer Genome Atlas Research N</collab>
                    <name>
                      <surname>Kandoth</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Schultz</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Cherniack</surname>
                      <given-names>AD</given-names>
                    </name>
                    <name>
                      <surname>Akbani</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Shen</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Robertson</surname>
                      <given-names>AG</given-names>
                    </name>
                    <name>
                      <surname>Pashtan</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Shen</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Benz</surname>
                      <given-names>CC</given-names>
                    </name>
                    <name>
                      <surname>Yau</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Laird</surname>
                      <given-names>PW</given-names>
                    </name>
                    <name>
                      <surname>Ding</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Zhang</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Mills</surname>
                      <given-names>GB</given-names>
                    </name>
                    <name>
                      <surname>Kucherlapati</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Mardis</surname>
                      <given-names>ER</given-names>
                    </name>
                    <name>
                      <surname>Levine</surname>
                      <given-names>DA</given-names>
                    </name>
                  </person-group>
                  <article-title>Integrated genomic characterization of endometrial carcinoma</article-title>
                  <source>Nature</source>
                  <year>2013</year>
                  <volume>497</volume>
                  <fpage>67</fpage>
                  <lpage>73</lpage>
                  <pub-id pub-id-type="doi">10.1038/nature12113</pub-id>
                  <pub-id pub-id-type="pmid">23636398</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Talhouk</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>McConechy</surname>
                      <given-names>MK</given-names>
                    </name>
                    <name>
                      <surname>Leung</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Lum</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Senz</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Boyd</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Pike</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Anglesio</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kwon</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Karnezis</surname>
                      <given-names>AN</given-names>
                    </name>
                    <name>
                      <surname>Huntsman</surname>
                      <given-names>DG</given-names>
                    </name>
                    <name>
                      <surname>Gilks</surname>
                      <given-names>CB</given-names>
                    </name>
                    <name>
                      <surname>McAlpine</surname>
                      <given-names>JN</given-names>
                    </name>
                  </person-group>
                  <article-title>Confirmation of ProMisE: a simple, genomics-based clinical classifier for endometrial cancer</article-title>
                  <source>Cancer</source>
                  <year>2017</year>
                  <volume>123</volume>
                  <fpage>802</fpage>
                  <lpage>813</lpage>
                  <pub-id pub-id-type="doi">10.1002/cncr.30496</pub-id>
                  <?supplied-pmid 28061006?>
                  <pub-id pub-id-type="pmid">28061006</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mahdi</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Chelariu-Raicu</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Slomovitz</surname>
                      <given-names>BM</given-names>
                    </name>
                  </person-group>
                  <article-title>Immunotherapy in endometrial cancer</article-title>
                  <source>Int J Gynecol Cancer</source>
                  <year>2023</year>
                  <volume>33</volume>
                  <fpage>351</fpage>
                  <lpage>357</lpage>
                  <pub-id pub-id-type="doi">10.1136/ijgc-2022-003675</pub-id>
                  <?supplied-pmid 36878570?>
                  <pub-id pub-id-type="pmid">36878570</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Santamaria Nunez</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Robles</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Giraudon</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Martinez-Leal</surname>
                      <given-names>JF</given-names>
                    </name>
                    <name>
                      <surname>Compe</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Coin</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Aviles</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Galmarini</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Egly</surname>
                      <given-names>JM</given-names>
                    </name>
                  </person-group>
                  <article-title>Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells</article-title>
                  <source>Mol Cancer Ther</source>
                  <year>2016</year>
                  <volume>15</volume>
                  <fpage>1</fpage>
                  <lpage>14</lpage>
                  <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-16-0172</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Leal</surname>
                      <given-names>JF</given-names>
                    </name>
                    <name>
                      <surname>Martinez-Diez</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Garcia-Hernandez</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Moneo</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Domingo</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Bueren-Calabuig</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Negri</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Gago</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Guillen-Navarro</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Aviles</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Cuevas</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Garcia-Fernandez</surname>
                      <given-names>LF</given-names>
                    </name>
                    <name>
                      <surname>Galmarini</surname>
                      <given-names>CM</given-names>
                    </name>
                  </person-group>
                  <article-title>PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti-tumour activity</article-title>
                  <source>Br J Pharmacol</source>
                  <year>2010</year>
                  <volume>161</volume>
                  <fpage>1099</fpage>
                  <lpage>1110</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.00945.x</pub-id>
                  <?supplied-pmid 20977459?>
                  <pub-id pub-id-type="pmid">20977459</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Harlow</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Maloney</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Roland</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Guillen Navarro</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Easton</surname>
                      <given-names>MK</given-names>
                    </name>
                    <name>
                      <surname>Kitchen-Goosen</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Boguslawski</surname>
                      <given-names>EA</given-names>
                    </name>
                    <name>
                      <surname>Madaj</surname>
                      <given-names>ZB</given-names>
                    </name>
                    <name>
                      <surname>Johnson</surname>
                      <given-names>BK</given-names>
                    </name>
                    <name>
                      <surname>Bowman</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>D'Incalci</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Winn</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Turner</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Hostetter</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Galmarini</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Aviles</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>Grohar</surname>
                      <given-names>PJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Lurbinectedin inactivates the ewing sarcoma oncoprotein EWS-FLI1 by redistributing it within the nucleus</article-title>
                  <source>Cancer Res</source>
                  <year>2016</year>
                  <volume>76</volume>
                  <fpage>6657</fpage>
                  <lpage>6668</lpage>
                  <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-0568</pub-id>
                  <?supplied-pmid 27697767?>
                  <pub-id pub-id-type="pmid">27697767</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Trigo</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Subbiah</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Besse</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Moreno</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>López</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Sala</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Peters</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ponce</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Fernández</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Alfaro</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Gómez</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Kahatt</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Zeaiter</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Zaman</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Boni</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Arrondeau</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Martínez</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Delord</surname>
                      <given-names>J-P</given-names>
                    </name>
                    <name>
                      <surname>Awada</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Kristeleit</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Olmedo</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Wannesson</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Valdivia</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Rubio</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Anton</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Sarantopoulos</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Chawla</surname>
                      <given-names>SP</given-names>
                    </name>
                    <name>
                      <surname>Mosquera-Martinez</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>D'Arcangelo</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Santoro</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Villalobos</surname>
                      <given-names>VM</given-names>
                    </name>
                    <name>
                      <surname>Sands</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Paz-Ares</surname>
                      <given-names>L</given-names>
                    </name>
                  </person-group>
                  <article-title>Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial</article-title>
                  <source>Lancet Oncol</source>
                  <year>2020</year>
                  <volume>21</volume>
                  <fpage>645</fpage>
                  <lpage>654</lpage>
                  <pub-id pub-id-type="doi">10.1016/S1470-2045(20)30068-1</pub-id>
                  <?supplied-pmid 32224306?>
                  <pub-id pub-id-type="pmid">32224306</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Singh</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Jaigirdar</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Mulkey</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Cheng</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Hamed</surname>
                      <given-names>SS</given-names>
                    </name>
                    <name>
                      <surname>Li</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Zhao</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Goheer</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Helms</surname>
                      <given-names>WS</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Agarwal</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Pragani</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Korsah</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Tang</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Leighton</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Rahman</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Beaver</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Pazdur</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Theoret</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Singh</surname>
                      <given-names>H</given-names>
                    </name>
                  </person-group>
                  <article-title>FDA approval summary: lurbinectedin for the treatment of metastatic small cell lung cancer</article-title>
                  <source>Clin Cancer Res</source>
                  <year>2021</year>
                  <volume>27</volume>
                  <fpage>2378</fpage>
                  <lpage>2382</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-3901</pub-id>
                  <?supplied-pmid 33288660?>
                  <pub-id pub-id-type="pmid">33288660</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Subbiah</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Brana</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Longhi</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Boni</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Delord</surname>
                      <given-names>JP</given-names>
                    </name>
                    <name>
                      <surname>Awada</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Boudou-Rouquette</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Sarantopoulos</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Shapiro</surname>
                      <given-names>GI</given-names>
                    </name>
                    <name>
                      <surname>Elias</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Ratan</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Fernandez</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Kahatt</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Cullell-Young</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Siguero</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Zeaiter</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Chawla</surname>
                      <given-names>SP</given-names>
                    </name>
                  </person-group>
                  <article-title>Antitumor activity of lurbinectedin, a selective inhibitor of oncogene transcription, in patients with relapsed ewing sarcoma: results of a basket phase II study</article-title>
                  <source>Clin Cancer Res</source>
                  <year>2022</year>
                  <volume>28</volume>
                  <fpage>2762</fpage>
                  <lpage>2770</lpage>
                  <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-22-0696</pub-id>
                  <?supplied-pmid 35486638?>
                  <pub-id pub-id-type="pmid">35486638</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kristeleit</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Moreno</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Boni</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Guerra</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Kahatt</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Romero</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Calvo</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Baste</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Lopez-Vilarino</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Siguero</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Alfaro</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Zeaiter</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Forster</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study</article-title>
                  <source>Int J Gynecol Cancer</source>
                  <year>2021</year>
                  <volume>31</volume>
                  <fpage>1428</fpage>
                  <lpage>1436</lpage>
                  <pub-id pub-id-type="doi">10.1136/ijgc-2021-002881</pub-id>
                  <?supplied-pmid 34610971?>
                  <pub-id pub-id-type="pmid">34610971</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McMeekin</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Dizon</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Barter</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Scambia</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Manzyuk</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Lisyanskaya</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Oaknin</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Ringuette</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Mukhopadhyay</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Rosenberg</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Vergote</surname>
                      <given-names>I</given-names>
                    </name>
                  </person-group>
                  <article-title>Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer</article-title>
                  <source>Gynecol Oncol</source>
                  <year>2015</year>
                  <volume>138</volume>
                  <fpage>18</fpage>
                  <lpage>23</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ygyno.2015.04.026</pub-id>
                  <?supplied-pmid 25925990?>
                  <pub-id pub-id-type="pmid">25925990</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Miller</surname>
                      <given-names>DS</given-names>
                    </name>
                    <name>
                      <surname>Scambia</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Bondarenko</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Westermann</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Oaknin</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Oza</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Lisyanskaya</surname>
                      <given-names>AS</given-names>
                    </name>
                    <name>
                      <surname>Vergote</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Wenham</surname>
                      <given-names>RM</given-names>
                    </name>
                    <name>
                      <surname>Temkin</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Gabra</surname>
                      <given-names>H</given-names>
                    </name>
                  </person-group>
                  <article-title>ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155)</article-title>
                  <source>J Clin Oncol</source>
                  <year>2018</year>
                  <volume>36</volume>
                  <fpage>5503</fpage>
                  <lpage>5503</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2018.36.15_suppl.5503</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Forster</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Moreno</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Boni</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Guerra</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Poveda</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Kristeleit</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Kahatt</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Lardelli</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Vilarino</surname>
                      <given-names>JAL</given-names>
                    </name>
                    <name>
                      <surname>Cuevas</surname>
                      <given-names>NM</given-names>
                    </name>
                    <name>
                      <surname>Soto-Matos</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Calvo</surname>
                      <given-names>E</given-names>
                    </name>
                  </person-group>
                  <article-title>Activity of lurbinectedin (PM01183) as single agent and in combination in patients with endometrial cancer</article-title>
                  <source>J Clin Oncol</source>
                  <year>2017</year>
                  <volume>35</volume>
                  <fpage>5586</fpage>
                  <lpage>5586</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2017.35.15_suppl.5586</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Eisenhauer</surname>
                      <given-names>EA</given-names>
                    </name>
                    <name>
                      <surname>Therasse</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Bogaerts</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Schwartz</surname>
                      <given-names>LH</given-names>
                    </name>
                    <name>
                      <surname>Sargent</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Ford</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Dancey</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Arbuck</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Gwyther</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Mooney</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Rubinstein</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Shankar</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Dodd</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Kaplan</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Lacombe</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Verweij</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)</article-title>
                  <source>Eur J Cancer</source>
                  <year>2009</year>
                  <volume>45</volume>
                  <fpage>228</fpage>
                  <lpage>247</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ejca.2008.10.026</pub-id>
                  <?supplied-pmid 19097774?>
                  <pub-id pub-id-type="pmid">19097774</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Oaknin</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Leon-Castillo</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Lorusso</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Progress in the management of endometrial cancer (subtypes, immunotherapy, alterations in PIK3CA pathway): data and perspectives</article-title>
                  <source>Curr Opin Oncol</source>
                  <year>2020</year>
                  <volume>32</volume>
                  <fpage>471</fpage>
                  <lpage>480</lpage>
                  <pub-id pub-id-type="doi">10.1097/CCO.0000000000000658</pub-id>
                  <?supplied-pmid 32740093?>
                  <pub-id pub-id-type="pmid">32740093</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Concin</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Matias-Guiu</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Vergote</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Cibula</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Mirza</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Marnitz</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ledermann</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Bosse</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Chargari</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Fagotti</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Fotopoulou</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Gonzalez Martin</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Lax</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Lorusso</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Marth</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Morice</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Nout</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>O'Donnell</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Querleu</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Raspollini</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Sehouli</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Sturdza</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Taylor</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Westermann</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Wimberger</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Colombo</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Planchamp</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Creutzberg</surname>
                      <given-names>CL</given-names>
                    </name>
                  </person-group>
                  <article-title>ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma</article-title>
                  <source>Int J Gynecol Cancer</source>
                  <year>2021</year>
                  <volume>31</volume>
                  <fpage>12</fpage>
                  <lpage>39</lpage>
                  <pub-id pub-id-type="doi">10.1136/ijgc-2020-002230</pub-id>
                  <?supplied-pmid 33397713?>
                  <pub-id pub-id-type="pmid">33397713</pub-id>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Aix</surname>
                      <given-names>SP</given-names>
                    </name>
                    <name>
                      <surname>Cote</surname>
                      <given-names>GM</given-names>
                    </name>
                    <name>
                      <surname>Gonzalez</surname>
                      <given-names>AF</given-names>
                    </name>
                    <name>
                      <surname>Sepulveda</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Aguilar</surname>
                      <given-names>EJ</given-names>
                    </name>
                    <name>
                      <surname>Sanchez-Simon</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Flor</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Nuñez</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Gonzalez</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Insa</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Siguero</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Cullell-Young</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Kahatt</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Zeaiter</surname>
                      <given-names>AH</given-names>
                    </name>
                    <name>
                      <surname>Paz-Ares</surname>
                      <given-names>LG</given-names>
                    </name>
                  </person-group>
                  <article-title>Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors: updated results from a phase Ib-II trial</article-title>
                  <source>J Clin Oncol</source>
                  <year>2020</year>
                  <volume>38</volume>
                  <fpage>3514</fpage>
                  <lpage>3514</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2020.38.15_suppl.3514</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kobel</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Ronnett</surname>
                      <given-names>BM</given-names>
                    </name>
                    <name>
                      <surname>Singh</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Soslow</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Gilks</surname>
                      <given-names>CB</given-names>
                    </name>
                    <name>
                      <surname>McCluggage</surname>
                      <given-names>WG</given-names>
                    </name>
                  </person-group>
                  <article-title>Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility</article-title>
                  <source>Int J Gynecol Pathol</source>
                  <year>2019</year>
                  <volume>38</volume>
                  <issue>Suppl 1</issue>
                  <fpage>S123</fpage>
                  <lpage>S131</lpage>
                  <pub-id pub-id-type="doi">10.1097/PGP.0000000000000488</pub-id>
                  <?supplied-pmid 29517499?>
                  <pub-id pub-id-type="pmid">29517499</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <mixed-citation publication-type="other">National Comprehensive Cancer Network (2022) NCCN clinical practice guidelines in oncology (NCCN Guidelines): uterine neoplasms. Version 1.2022 – November 4, 2021. <ext-link ext-link-type="uri" xlink:href="http://www.nccn.org/professionals/default.aspx">http://www.nccn.org/professionals/default.aspx</ext-link>. Accessed 22 March 2023</mixed-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <mixed-citation publication-type="other">Makker V, Herraez A, Santin A, Colomba E, Miller D, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim Y, Guerra E, Sanli U, McCormack M, Huang J, Smith A, Keefe S, Dutta L, Orlowski R, Lorusso D (2021) A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer. Study 309/KEYNOTE-775 Society of Gynecologic Oncology 2021 Annual Meeting on Women’s Cancer. Abstract 11512</mixed-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Cruz</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Llop-Guevara</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Garber</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Arun</surname>
                      <given-names>BK</given-names>
                    </name>
                    <name>
                      <surname>Perez Fidalgo</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Lluch</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Telli</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Fernandez</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Kahatt</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Galmarini</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Soto-Matos</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Alfaro</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Perez de la Haza</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Domchek</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Antolin</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Vahdat</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Tung</surname>
                      <given-names>NM</given-names>
                    </name>
                    <name>
                      <surname>Lopez</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Arribas</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Vivancos</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Baselga</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Serra</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Balmana</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Isakoff</surname>
                      <given-names>SJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Multicenter phase II study of lurbinectedin in BRCA-mutated and unselected metastatic advanced breast cancer and biomarker assessment substudy</article-title>
                  <source>J Clin Oncol</source>
                  <year>2018</year>
                  <volume>36</volume>
                  <fpage>3134</fpage>
                  <lpage>3143</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.2018.78.6558</pub-id>
                  <?supplied-pmid 30240327?>
                  <pub-id pub-id-type="pmid">30240327</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Longo-Muñoz</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Castellano</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Alexandre</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Chawla</surname>
                      <given-names>SP</given-names>
                    </name>
                    <name>
                      <surname>Fernández</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Kahatt</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Alfaro</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Siguero</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Zeaiter</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Moreno</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Sanz-García</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Awada</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Santaballa</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Subbiah</surname>
                      <given-names>V</given-names>
                    </name>
                  </person-group>
                  <article-title>Lurbinectedin in patients with pretreated neuroendocrine tumours: results from a phase II basket study</article-title>
                  <source>Eur J Cancer</source>
                  <year>2022</year>
                  <volume>172</volume>
                  <fpage>340</fpage>
                  <lpage>348</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ejca.2022.06.024</pub-id>
                  <?supplied-pmid 35830841?>
                  <pub-id pub-id-type="pmid">35830841</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Poveda</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Del Campo</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Ray-Coquard</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Alexandre</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Provansal</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Guerra Alia</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Casado</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Gonzalez-Martin</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Fernandez</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Rodriguez</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Soto</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Kahatt</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Fernandez Teruel</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Galmarini</surname>
                      <given-names>CM</given-names>
                    </name>
                    <name>
                      <surname>Perez de la Haza</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Bohan</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Berton-Rigaud</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer</article-title>
                  <source>Ann Oncol</source>
                  <year>2017</year>
                  <volume>28</volume>
                  <fpage>1280</fpage>
                  <lpage>1287</lpage>
                  <pub-id pub-id-type="doi">10.1093/annonc/mdx111</pub-id>
                  <?supplied-pmid 28368437?>
                  <pub-id pub-id-type="pmid">28368437</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gaillard</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Oaknin</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Ray-Coquard</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Vergote</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Scambia</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Colombo</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Fernandez</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Alfaro</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Kahatt</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Nieto</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Zeaiter</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Aracil</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Vidal</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Pardo-Burdalo</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Papai</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Kristeleit</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>O'Malley</surname>
                      <given-names>DM</given-names>
                    </name>
                    <name>
                      <surname>Benjamin</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Pautier</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Lorusso</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: a multicenter, randomized, controlled, open-label phase 3 study (CORAIL)</article-title>
                  <source>Gynecol Oncol</source>
                  <year>2021</year>
                  <volume>163</volume>
                  <fpage>237</fpage>
                  <lpage>245</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.ygyno.2021.08.032</pub-id>
                  <?supplied-pmid 34521554?>
                  <pub-id pub-id-type="pmid">34521554</pub-id>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mirza</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Chase</surname>
                      <given-names>DM</given-names>
                    </name>
                    <name>
                      <surname>Slomovitz</surname>
                      <given-names>BM</given-names>
                    </name>
                    <name>
                      <surname>dePont</surname>
                      <given-names>CR</given-names>
                    </name>
                    <name>
                      <surname>Novak</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Black</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Gilbert</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Sharma</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Valabrega</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Landrum</surname>
                      <given-names>LM</given-names>
                    </name>
                    <name>
                      <surname>Hanker</surname>
                      <given-names>LC</given-names>
                    </name>
                    <name>
                      <surname>Stuckey</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Boere</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Gold</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Auranen</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Pothuri</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Cibula</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>McCourt</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Raspagliesi</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Shahin</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Gill</surname>
                      <given-names>SE</given-names>
                    </name>
                    <name>
                      <surname>Monk</surname>
                      <given-names>BJ</given-names>
                    </name>
                    <name>
                      <surname>Buscema</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Herzog</surname>
                      <given-names>TJ</given-names>
                    </name>
                    <name>
                      <surname>Copeland</surname>
                      <given-names>LJ</given-names>
                    </name>
                    <name>
                      <surname>Tian</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>He</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Stevens</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Zografos</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Coleman</surname>
                      <given-names>RL</given-names>
                    </name>
                    <name>
                      <surname>Powell</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Investigators</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Dostarlimab for primary advanced or recurrent endometrial cancer</article-title>
                  <source>N Engl J Med</source>
                  <year>2023</year>
                  <volume>388</volume>
                  <fpage>2145</fpage>
                  <lpage>2158</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa2216334</pub-id>
                  <?supplied-pmid 36972026?>
                  <pub-id pub-id-type="pmid">36972026</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Eskander</surname>
                      <given-names>RN</given-names>
                    </name>
                    <name>
                      <surname>Sill</surname>
                      <given-names>MW</given-names>
                    </name>
                    <name>
                      <surname>Beffa</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Moore</surname>
                      <given-names>RG</given-names>
                    </name>
                    <name>
                      <surname>Hope</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Musa</surname>
                      <given-names>FB</given-names>
                    </name>
                    <name>
                      <surname>Mannel</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Shahin</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Cantuaria</surname>
                      <given-names>GH</given-names>
                    </name>
                    <name>
                      <surname>Girda</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Mathews</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Kavecansky</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Leath</surname>
                      <given-names>CA</given-names>
                      <suffix>3rd</suffix>
                    </name>
                    <name>
                      <surname>Gien</surname>
                      <given-names>LT</given-names>
                    </name>
                    <name>
                      <surname>Hinchcliff</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Lele</surname>
                      <given-names>SB</given-names>
                    </name>
                    <name>
                      <surname>Landrum</surname>
                      <given-names>LM</given-names>
                    </name>
                    <name>
                      <surname>Backes</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>O'Cearbhaill</surname>
                      <given-names>RE</given-names>
                    </name>
                    <name>
                      <surname>Al Baghdadi</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Hill</surname>
                      <given-names>EK</given-names>
                    </name>
                    <name>
                      <surname>Thaker</surname>
                      <given-names>PH</given-names>
                    </name>
                    <name>
                      <surname>John</surname>
                      <given-names>VS</given-names>
                    </name>
                    <name>
                      <surname>Welch</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Fader</surname>
                      <given-names>AN</given-names>
                    </name>
                    <name>
                      <surname>Powell</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Aghajanian</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Pembrolizumab plus chemotherapy in advanced endometrial cancer</article-title>
                  <source>N Engl J Med</source>
                  <year>2023</year>
                  <volume>388</volume>
                  <fpage>2159</fpage>
                  <lpage>2170</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa2302312</pub-id>
                  <?supplied-pmid 36972022?>
                  <pub-id pub-id-type="pmid">36972022</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>O'Malley</surname>
                      <given-names>DM</given-names>
                    </name>
                    <name>
                      <surname>Bariani</surname>
                      <given-names>GM</given-names>
                    </name>
                    <name>
                      <surname>Cassier</surname>
                      <given-names>PA</given-names>
                    </name>
                    <name>
                      <surname>Marabelle</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Hansen</surname>
                      <given-names>AR</given-names>
                    </name>
                    <name>
                      <surname>De Jesus</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Miller</surname>
                      <given-names>WH</given-names>
                      <suffix>Jr</suffix>
                    </name>
                    <name>
                      <surname>Safra</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Italiano</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Mileshkin</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Xu</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Jin</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Norwood</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Maio</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study</article-title>
                  <source>J Clin Oncol</source>
                  <year>2022</year>
                  <volume>40</volume>
                  <fpage>752</fpage>
                  <lpage>761</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.21.01874</pub-id>
                  <?supplied-pmid 34990208?>
                  <pub-id pub-id-type="pmid">34990208</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Oaknin</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Gilbert</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Tinker</surname>
                      <given-names>AV</given-names>
                    </name>
                    <name>
                      <surname>Brown</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Mathews</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Press</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Sabatier</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>O'Malley</surname>
                      <given-names>DM</given-names>
                    </name>
                    <name>
                      <surname>Samouelian</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Boni</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Duska</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Ghamande</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ghatage</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Kristeleit</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Leath</surname>
                      <given-names>C</given-names>
                      <suffix>III</suffix>
                    </name>
                    <name>
                      <surname>Guo</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Im</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Zildjian</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Han</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Duan</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Veneris</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Pothuri</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study</article-title>
                  <source>J Immunother Cancer</source>
                  <year>2022</year>
                  <volume>10</volume>
                  <fpage>e003777</fpage>
                  <pub-id pub-id-type="doi">10.1136/jitc-2021-003777</pub-id>
                  <?supplied-pmid 35064011?>
                  <pub-id pub-id-type="pmid">35064011</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Makker</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Colombo</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Herraez</surname>
                      <given-names>AC</given-names>
                    </name>
                    <name>
                      <surname>Monk</surname>
                      <given-names>BJ</given-names>
                    </name>
                    <name>
                      <surname>Mackay</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Santin</surname>
                      <given-names>AD</given-names>
                    </name>
                    <name>
                      <surname>Miller</surname>
                      <given-names>DS</given-names>
                    </name>
                    <name>
                      <surname>Moore</surname>
                      <given-names>RG</given-names>
                    </name>
                    <name>
                      <surname>Baron-Hay</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ray-Coquard</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Ushijima</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Yonemori</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Kim</surname>
                      <given-names>YM</given-names>
                    </name>
                    <name>
                      <surname>Guerra Alia</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Sanli</surname>
                      <given-names>UA</given-names>
                    </name>
                    <name>
                      <surname>Bird</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Orlowski</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>McKenzie</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Okpara</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Barresi</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Lorusso</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III study 309/KEYNOTE-775</article-title>
                  <source>J Clin Oncol</source>
                  <year>2023</year>
                  <volume>41</volume>
                  <fpage>2904</fpage>
                  <lpage>2910</lpage>
                  <pub-id pub-id-type="doi">10.1200/JCO.22.02152</pub-id>
                  <?supplied-pmid 37058687?>
                  <pub-id pub-id-type="pmid">37058687</pub-id>
                </element-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
